Compare LCUT & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | AGEN |
|---|---|---|
| Founded | 1945 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.2M | 178.2M |
| IPO Year | 1996 | 1999 |
| Metric | LCUT | AGEN |
|---|---|---|
| Price | $6.78 | $3.92 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $14.50 |
| AVG Volume (30 Days) | 157.5K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $647,933,000.00 | $42,877,086.00 |
| Revenue This Year | $3.74 | $107.63 |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | $8.89 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $2.89 | $2.71 |
| 52 Week High | $8.20 | $7.34 |
| Indicator | LCUT | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.91 | 49.53 |
| Support Level | $6.50 | $2.96 |
| Resistance Level | $8.20 | $4.58 |
| Average True Range (ATR) | 0.57 | 0.36 |
| MACD | -0.16 | -0.08 |
| Stochastic Oscillator | 18.13 | 19.10 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.